Competition between H4PteGlu and H2PtePAS Confers para-Aminosalicylic Acid Resistance in Mycobacterium tuberculosis
- PMID: 38275323
- PMCID: PMC10812664
- DOI: 10.3390/antibiotics13010013
Competition between H4PteGlu and H2PtePAS Confers para-Aminosalicylic Acid Resistance in Mycobacterium tuberculosis
Abstract
Tuberculosis remains a serious challenge to human health worldwide. para-Aminosalicylic acid (PAS) is an important anti-tuberculosis drug, which requires sequential activation by Mycobacterium tuberculosis (M. tuberculosis) dihydropteroate synthase and dihydrofolate synthase (DHFS, FolC). Previous studies showed that loss of function mutations of a thymidylate synthase coding gene thyA caused PAS resistance in M. tuberculosis, but the mechanism is unclear. Here we showed that deleting thyA in M. tuberculosis resulted in increased content of tetrahydrofolate (H4PteGlu) in bacterial cells as they rely on the other thymidylate synthase ThyX to synthesize thymidylate, which produces H4PteGlu during the process. Subsequently, data of in vitro enzymatic activity experiments showed that H4PteGlu hinders PAS activation by competing with hydroxy dihydropteroate (H2PtePAS) for FolC catalysis. Meanwhile, over-expressing folC in ΔthyA strain and a PAS resistant clinical isolate with known thyA mutation partially restored PAS sensitivity, which relieved the competition between H4PteGlu and H2PtePAS. Thus, loss of function mutations in thyA led to increased H4PteGlu content in bacterial cells, which competed with H2PtePAS for catalysis by FolC and hence hindered the activation of PAS, leading to decreased production of hydroxyl dihydrofolate (H2PtePAS-Glu) and finally caused PAS resistance. On the other hand, functional deficiency of thyA in M. tuberculosis pushes the bacterium switch to an unidentified dihydrofolate reductase for H4PteGlu biosynthesis, which might also contribute to the PAS resistance phenotype. Our study revealed how thyA mutations confer PAS resistance in M. tuberculosis and provided new insights into studies on the folate metabolism of the bacterium.
Keywords: Mycobacterium tuberculosis; para-aminosalicylic acid; tetrahydrofolate; thyA.
Conflict of interest statement
The authors declare no conflict of interest.
Figures





Similar articles
-
Determination of critical concentration for drug susceptibility testing of Mycobacterium tuberculosis against para-aminosalicylic acid with clinical isolates with thyA, folC and dfrA mutations.Ann Clin Microbiol Antimicrob. 2022 Nov 5;21(1):48. doi: 10.1186/s12941-022-00537-z. Ann Clin Microbiol Antimicrob. 2022. PMID: 36335391 Free PMC article.
-
Binding pocket alterations in dihydrofolate synthase confer resistance to para-aminosalicylic acid in clinical isolates of Mycobacterium tuberculosis.Antimicrob Agents Chemother. 2014;58(3):1479-87. doi: 10.1128/AAC.01775-13. Epub 2013 Dec 23. Antimicrob Agents Chemother. 2014. PMID: 24366731 Free PMC article.
-
[Mutations in the thymidylate synthase gene is a major mechanism in the para-aminosalicylic acid resistance of M. tuberculosis].Zhonghua Jie He He Hu Xi Za Zhi. 2007 Sep;30(9):683-5. Zhonghua Jie He He Hu Xi Za Zhi. 2007. PMID: 18070553 Chinese.
-
Mycobacterium tuberculosis folate metabolism and the mechanistic basis for para-aminosalicylic acid susceptibility and resistance.Antimicrob Agents Chemother. 2015 Sep;59(9):5097-106. doi: 10.1128/AAC.00647-15. Epub 2015 Jun 1. Antimicrob Agents Chemother. 2015. PMID: 26033719 Free PMC article. Review.
-
The aminosalicylate - folate connection.Drug Metab Rev. 2024 Feb;56(1):80-96. doi: 10.1080/03602532.2024.2303507. Epub 2024 Jan 17. Drug Metab Rev. 2024. PMID: 38230664 Free PMC article. Review.
Cited by
-
The T120P or M172V mutation on rv2172c confers high level para-aminosalicylic acid resistance in Mycobacterium tuberculosis.Emerg Microbes Infect. 2024 Dec;13(1):2374030. doi: 10.1080/22221751.2024.2374030. Epub 2024 Jul 24. Emerg Microbes Infect. 2024. PMID: 39023395 Free PMC article.
-
Genetic diversity and transmission pattern of multidrug-resistant tuberculosis based on whole-genome sequencing in Wuhan, China.Front Public Health. 2025 Jan 28;13:1442987. doi: 10.3389/fpubh.2025.1442987. eCollection 2025. Front Public Health. 2025. PMID: 39935875 Free PMC article.
References
-
- World Health Organization (WHO) Global Tuberculosis Report 2022. World Health Organization; Geneva, Switzerland: 2022.
-
- Thibault P. Rifampicine, new antitubercular drug. Presse Med. 1967;75:2816. - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources